Navigation Links
All-Oral Combination Study with PSI-7977 for HCV Genotypes 1, 2 and 3 Initiated
Date:5/26/2011

PRINCETON, N.J., May 26, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today the initiation of a Phase 2a trial investigating the combination of Pharmasset's PSI-7977, a nucleotide polymerase inhibitor, and BMS-790052, Bristol-Myers Squibb Company's (NYSE: BMY) NS5A replication complex inhibitor, for the treatment of chronic hepatitis C (HCV).  This trial is the result of a clinical collaboration agreement between Pharmasset and Bristol-Myers Squibb announced in January 2011.

"We are happy to announce the initiation of this important combination trial," stated William Symonds, Pharmasset's Senior Vice President of Clinical Pharmacology and Translational Medicine. "Recent data from Bristol-Myers Squibb's combination study demonstrated that individuals with HCV can be cured without the traditional interferon and ribavirin, but only if two potent DAAs are used and drug resistance is avoided. We believe Pharmasset's nucleotide analogs have demonstrated potent antiviral activity and a high barrier to resistance and therefore have the potential to be the future backbone of interferon-free treatment."

About the Trial

This Phase 2a trial is planned to enroll approximately 84 patients with chronic HCV genotypes 1, 2 or 3 who have not been treated previously. The primary endpoint of the trial is sustained virologic response (SVR). The trial will be conducted in the U.S. Subjects will be randomized equally across each of the following arms:

  • PSI-7977 400mg QD for 7 days, then add BMS-790052 60mg QD for further 23 weeks in genotype 1 subjects;
  • PSI-7977 400mg QD for 7 days, then add BMS-790052 60mg QD for further 23 weeks in genotype 2 or 3 subjects;
  • PSI-7977 400mg QD and BMS-790052 60mg QD for 24 weeks in g
    '/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
2. Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad in Combination With Allopurinol at the Annual European Congress of Rheumatology
3. Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study
4. ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor
5. Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products
6. Particle Sciences and Celanese EVA Performance Polymers Collaborate to Accelerate Drug-Eluting Device Combinations
7. Jennerex and Green Cross Announce Publication of Positive Clinical Data of JX-594 in Combination With Sorafenib in Advanced Liver Cancer
8. Merrimack Pharmaceuticals Announces that Recruitment is Open in a Phase 1 Combination Study of MM-111 with Multiple Treatment Regimens in HER2 Positive Patients
9. New Interim Data About Combination Oral Contraceptives
10. Syndax Announces Start of NCI Sponsored Phase 2 Study of Entinostat in Combination in Triple Negative Breast Cancer
11. Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... DUBLIN , Aug. 29, 2014 ... the "China Orthopedic Instrument Industry Report, 2014-2017" ... accelerated aging population and rising proportion of reimbursement for ... been effectively released, with its scale presenting a CAGR ... joint products are three product segments of orthopedic instruments ...
(Date:8/29/2014)... Research and Markets  has announced the addition of the ... their offering. The Central Nervous System (CNS) ... of pharmaceuticals industry. The numbers of CNS disorders have increased ... to meet the market requirements. There has been steady to ... the past two decades. The market for CNS therapies is ...
(Date:8/29/2014)... DENVER , Aug. 29, 2014 Does your ... date, nearly 800 doctors have recommended marijuana to the over ... Amendment 20. But the majority of the other roughly 20,300+ ... still know very little about it – even though a ... adults say they have tried it. ...
Breaking Medicine Technology:China Orthopedic Instrument Industry Report, 2014-2017 2US CNS Disorders Drug Pipeline Insight 2014 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4
... 2012 OPKO Health, Inc. and ChromaDex Corporation (OTCBB: ... alliance pursuant to which ChromaDex has licensed to OPKO ... technologies for distribution and business development throughout all of ... BluScience™ ( www.bluscience.com ), ChromaDex,s recently launched ...
... 2012 Uroplasty, Inc. (NASDAQ: UPI ), ... innovative proprietary products to treat voiding dysfunctions, today announced ... study in the United Kingdom. This large ... up to 20 centers across the UK. Using Uroplasty,s ...
Cached Medicine Technology:OPKO Health, Inc. Invests in ChromaDex® Corp. 2OPKO Health, Inc. Invests in ChromaDex® Corp. 3OPKO Health, Inc. Invests in ChromaDex® Corp. 4OPKO Health, Inc. Invests in ChromaDex® Corp. 5Uroplasty Announces Enrollment of First Patients in the CONFIDeNT Clinical Study for Treatment of Fecal Incontinence with Urgent® PC 2Uroplasty Announces Enrollment of First Patients in the CONFIDeNT Clinical Study for Treatment of Fecal Incontinence with Urgent® PC 3
(Date:8/29/2014)... LiveOps, Inc., the global leader in cloud ... LiveOps has been selected as a call center provider ... Telethon for the third year in a row. This ... support MDA’s mission to help children and adults affected ... disease. This year’s program includes performances by Bret Michaels, ...
(Date:8/29/2014)... Thirteen Novant Health registered nurses have ... in North Carolina list by Great 100, Inc., ... to nursing students at all levels across the state. ... Medical Center are: Rea Buie, Carol Caldwell, Susan ... Amber Segerlin, Carmen Smith, Melissa Stafford and Deborah Stegall. ...
(Date:8/29/2014)... Steven Reinberg HealthDay ... -- The vast majority of American babies are getting ... illnesses, federal health officials said Thursday. More than ... prevent measles, mumps, and rubella (MMR); polio; hepatitis B ... Disease Control and Prevention. "Nationally, vaccination among children ...
(Date:8/29/2014)... EDMONTON, AB A new study from the research group ... AB) and the Lawson Health Research Institute (London, ON) has ... of cancer. The study, published in Cell Reports , ... spread of cancer entirely. , Roughly 2 in 5 ... four of them will die of the disease. In 2014, ...
(Date:8/29/2014)... Pittsburgh, PA (PRWEB) August 29, 2014 ... be slippery, especially when wearing socks. Also, many patients ... ambulatory problems, poor balance, surgery recovery, Alzheimer’s, etc. Two ... in order to optimize patient safety. , This special ... medical-facility floors. It also keeps patients who are relegated ...
Breaking Medicine News(10 mins):Health News:LiveOps Supports Muscular Dystrophy Association Show of Strength Telethon 2Health News:LiveOps Supports Muscular Dystrophy Association Show of Strength Telethon 3Health News:LiveOps Supports Muscular Dystrophy Association Show of Strength Telethon 4Health News:Great 100 Honors 13 Novant Health Nurses 2Health News:Most U.S. Babies Get Their Vaccines: CDC 2Health News:Most U.S. Babies Get Their Vaccines: CDC 3Health News:Preventing cancer from forming 'tentacles' stops dangerous spread 2
... , , , , ... and all MinuteClinic medical clinics throughout Arizona are now offering H1N1 ... MinuteClinic locations in Illinois in the Chicago area and in Nevada ... with no appointment necessary. Priority group restrictions have been lifted in ...
... ... tooth whitening procedures. , ... CA (PRWEB) Dec. 21, 2009 -- If you are thinking about giving the gift of ... have all the facts to become a smart shopper of this popular cosmetic process. , ...
... rats when resin was part of diet, study finds , ... in the Middle East -- known as myrrh -- may ... author explained that myrrh resin could be used in conjunction ... not clear yet how people might consume it, and more ...
... , CANTON, Mass., Dec. 21 Organogenesis, Inc. ... (PMA) with the U.S. Food and Drug Administration (FDA) for ... regeneration. If approved, CelTx will be the first, living ... market. , A pioneer in the field, Organogenesis ...
... , CHESTERFIELD, Mo., Dec. 21 ... scientific officer of Reliv International, Inc., was elected to the ... the nation,s leading trade association for the dietary supplement industry. ... control and manufacturing for Reliv, a direct selling company of ...
... , , SANTA CLARA, Calif., Dec. ... in enterprise mobility, today announced that it swept top honors ... MobileVillage® Mobile Star Awards(TM) program, as a result of industry ... and news services about mobile technology. , As in past ...
Cached Medicine News:Health News:CVS/pharmacy and MinuteClinic Now Providing H1N1 Vaccinations in Arizona 2Health News:CVS/pharmacy and MinuteClinic Now Providing H1N1 Vaccinations in Arizona 3Health News:Dreaming of a Whiter Christmas and New Year for Your Teeth? 2Health News:Organogenesis Files PMA for CelTx(TM) for Oral Soft Tissue Regeneration 2Health News:Organogenesis Files PMA for CelTx(TM) for Oral Soft Tissue Regeneration 3Health News:Reliv International's Carl W. Hastings Elected to Board of the Council for Responsible Nutrition 2Health News:Industry Names Agito Networks, Company CTO, FMC Customer to Top MobileVillage Honors for 2009 2Health News:Industry Names Agito Networks, Company CTO, FMC Customer to Top MobileVillage Honors for 2009 3Health News:Industry Names Agito Networks, Company CTO, FMC Customer to Top MobileVillage Honors for 2009 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: